Our reputation has been gained through the successful conduct of over 500 Early Phase Studies since inception in 2001, ranging from testing Anaesthetic agents to Zinamide interaction studies. The specialist areas in which we have really excelled over many years are Adaptive, Thorough-QT, Japanese Bridging Studies and Patient Recruitment – evident in the numerous peer-reviewed papers we have published.

UK's leading clinical research organisation

Our business ethos is unique: Our revenues serve the National Health Service and St George’s University of London, fund basic research, support charities or otherwise are reinvested in the business. Our business is sustainable, adaptive to change and is led by the same specialists who founded the business more than ten years ago.

All our sponsors are preferred clients. Richmond Pharmacology’s interaction with its sponsors is personal and truly strategic, generating enhanced value for drug developers and investors.

Our work is closely supervised throughout by the same senior specialists sponsors meet during the first consultation or bid defence. Our services span strategic consultancy and concept development through to final reporting, utilising our many years of experience and leading to successful clinical trials with meaningful results.

Work with our experts

Conduct your trial in a cost effective and timely manner

Get in touch today

Latest news

COVID-19 – External Monitoring Guidelines

01st Jul 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing

Read more ›

Update on COVID-19

29th May 2020

Richmond Pharmacology update on SARS-CoV-2 infection control and management of clinical trials

Read more ›

Statement on COVID-19

23rd Mar 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are

Read more ›

On Helix, Transforming new medicine discovery

Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON

View event ›